Measuring the impact of ambulatory red blood cell transfusion on home functional status: study protocol for a pilot randomized controlled trial

Abstract

BackgroundRed blood cell (RBC) transfusion is frequently employed in both ambulatory and hospital environments with the aim of improving patient functional status. In the ambulatory setting, this practice is particularly common in patients with malignancy due to anemia associated with their cancer therapy. Increasingly, the efficacy of this US$10.5 billion per year practice has been called into question. While it is often standard of care for patients with chemotherapy-induced anemia to receive ambulatory RBC transfusions, it is unclear to what extent such transfusions affect home functional status. It is also unclear whether or not changes in functional status in this population can be objectively quantified using wearable activity monitors. We propose to directly measure the impact of outpatient RBC transfusions on at-home functional status by recording several physiological parameters and quantifiable physical activity metrics, e.g., daily energy expenditure and daily total step count, using the ActiGraph wGT3X-BT. This device is an accelerometer-based wearable activity monitor similar in size to a small watch and is worn at the waist. Study participants will wear the device during the course of their daily activities giving us quantifiable insight into activity levels in the home environment.Methods/designThis will be a randomized crossover pilot clinical trial with a participant study duration of 28 days. The crossover nature allows each patient to serve as their own control. Briefly, patients presenting at a tertiary medical center’s Ambulatory Infusion Center (AIC) will be randomized to either: (1) receive an RBC transfusion as scheduled (transfusion) or (2) abstain from the scheduled transfusion (no transfusion). After an appropriate washout period, participants will crossover from the transfusion arm to the no-transfusion arm or vice versa. Activity levels will be recorded continuously throughout the study using an accelerometry monitor. In addition to device data, functional status and health outcomes will be collected via a weekly telephone interview. The primary outcome measure will be daily energy expenditure. Performance metrics, such as step count changes, will also be evaluated. Additional secondary outcome measures will include daily sedentary time and Patient-reported Outcomes Measurement Information System (PROMIS) Global 10 Survey scores.DiscussionThis trial will provide important information on the feasibility and utility of using accelerometry monitors to directly assess the impact of RBC transfusion on patients’ functional status. The results of the study will inform the merit and methods of a more definitive future trial evaluating the impact of ambulatory RBC transfusions in the target population.Trial registrationClinicalTrials.gov, identifier: NCT02835937. Registered on 15 July 2016.Electronic supplementary materialThe online version of this article (doi:10.1186/s13063-017-1873-z) contains supplementary material, which is available to authorized users.

Therapeutic impact of red blood cell transfusion on anemic outpatients: the RETRO study

“…We showed that transfusion is associated with clinically important improvement in two of these outcomes: walk test distance and fatigue. To define which patients might benefit from transfusion, future studies could include data from wearable monitors to capture effect of RBC on vital signs and physical activity or noninvasive measurement of oxygen saturation to capture tissue response to transfusion . Such data, combined with pretransfusion Hb levels and results of patient‐centered outcome studies like RETRO, will help clinicians personalize the decision to transfuse oncology patients.…”

Red cell transfusions: Is less always best?

“…54,55 Sarcopenia, tested via handgrip strength using a hand dynamometer, has been associated with anemia, however, the effect of transfusion is unclear. 56 There is also increasing interest in the use of wearable non-invasive accelerometers 57 to capture the effect of transfusion on daily physical activity.…”

Does packed red cell transfusion provide symptomatic benefits to cancer palliative patients?: a longitudinal study from a single private oncology center in Nepal

“…Studies on beneficial effects of transfusion in cancer palliative patients are highly inconclusive, and blood transfusion is highly individualized [9]. Rather than being dictated by hemoglobin (Hb) values, transfusion of blood products should be aimed at improving the functional status and QoL [10–13]. Hemoglobin is the most widely accepted standard transfusion trigger in all anemic patients and is usually based on subjective symptoms of easy fatigability, shortness of breath and lethargy [14].…”